Why a thoughtful approach to portfolio strategy can enable pharma cos in Japan to grow, even while the market stays flat

8 April 2022
japan_bridge_large

A Feature on the Japanese pharma market from Patrick Branch, a Partner in LEK's Tokyo office and a member of the firm’s Life Sciences practice.

A unique market

Japan is a special place for many reasons – highlights are many, and include a unique and delicious cuisine, delightful customs and culture, and a varied geography including both snowy peaks and tropical seas. Japan is also a standout among its major pharmaceutical market peers – but not necessarily for good reasons.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical